|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FGFR1 |
Gene summary for FGFR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FGFR1 | Gene ID | 2260 |
| Gene name | fibroblast growth factor receptor 1 | |
| Gene Alias | BFGFR | |
| Cytomap | 8p11.23 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A0S2Z3Q6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2260 | FGFR1 | GSM4909285 | Human | Breast | IDC | 1.53e-02 | -2.04e-01 | 0.21 |
| 2260 | FGFR1 | GSM4909286 | Human | Breast | IDC | 3.09e-02 | 1.03e-01 | 0.1081 |
| 2260 | FGFR1 | GSM4909290 | Human | Breast | IDC | 6.87e-03 | -2.37e-01 | 0.2096 |
| 2260 | FGFR1 | GSM4909293 | Human | Breast | IDC | 8.12e-05 | -2.23e-01 | 0.1581 |
| 2260 | FGFR1 | GSM4909296 | Human | Breast | IDC | 1.88e-09 | -2.55e-01 | 0.1524 |
| 2260 | FGFR1 | GSM4909297 | Human | Breast | IDC | 6.43e-13 | 5.19e-01 | 0.1517 |
| 2260 | FGFR1 | GSM4909311 | Human | Breast | IDC | 3.45e-10 | -2.51e-01 | 0.1534 |
| 2260 | FGFR1 | GSM4909312 | Human | Breast | IDC | 7.27e-12 | -2.63e-01 | 0.1552 |
| 2260 | FGFR1 | GSM4909315 | Human | Breast | IDC | 1.71e-05 | -2.42e-01 | 0.21 |
| 2260 | FGFR1 | GSM4909319 | Human | Breast | IDC | 1.69e-10 | -2.58e-01 | 0.1563 |
| 2260 | FGFR1 | GSM4909320 | Human | Breast | IDC | 2.26e-02 | -2.63e-01 | 0.1575 |
| 2260 | FGFR1 | GSM4909321 | Human | Breast | IDC | 3.57e-08 | -2.54e-01 | 0.1559 |
| 2260 | FGFR1 | ctrl6 | Human | Breast | Precancer | 1.20e-07 | 5.06e-01 | -0.0061 |
| 2260 | FGFR1 | brca10 | Human | Breast | Precancer | 3.65e-02 | 3.24e-01 | -0.0029 |
| 2260 | FGFR1 | NCCBC5 | Human | Breast | DCIS | 1.72e-02 | -2.14e-01 | 0.2046 |
| 2260 | FGFR1 | P1 | Human | Breast | IDC | 4.06e-04 | -2.21e-01 | 0.1527 |
| 2260 | FGFR1 | DCIS2 | Human | Breast | DCIS | 8.89e-24 | -7.00e-02 | 0.0085 |
| 2260 | FGFR1 | AEH-subject3 | Human | Endometrium | AEH | 3.78e-04 | 2.96e-01 | -0.2576 |
| 2260 | FGFR1 | AEH-subject5 | Human | Endometrium | AEH | 2.43e-23 | 7.20e-01 | -0.2953 |
| 2260 | FGFR1 | EEC-subject1 | Human | Endometrium | EEC | 1.80e-12 | 5.07e-01 | -0.2682 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
| GO:00603266 | Breast | Precancer | cell chemotaxis | 41/1080 | 310/18723 | 5.99e-07 | 2.55e-05 | 41 |
| GO:20012369 | Breast | Precancer | regulation of extrinsic apoptotic signaling pathway | 24/1080 | 151/18723 | 5.78e-06 | 1.70e-04 | 24 |
| GO:00971919 | Breast | Precancer | extrinsic apoptotic signaling pathway | 30/1080 | 219/18723 | 9.42e-06 | 2.50e-04 | 30 |
| GO:00106348 | Breast | Precancer | positive regulation of epithelial cell migration | 25/1080 | 176/18723 | 2.75e-05 | 6.21e-04 | 25 |
| GO:00321034 | Breast | Precancer | positive regulation of response to external stimulus | 46/1080 | 427/18723 | 3.41e-05 | 7.40e-04 | 46 |
| GO:00106319 | Breast | Precancer | epithelial cell migration | 40/1080 | 357/18723 | 4.57e-05 | 9.71e-04 | 40 |
| GO:00901329 | Breast | Precancer | epithelium migration | 40/1080 | 360/18723 | 5.51e-05 | 1.14e-03 | 40 |
| GO:00506736 | Breast | Precancer | epithelial cell proliferation | 46/1080 | 437/18723 | 6.02e-05 | 1.23e-03 | 46 |
| GO:00435426 | Breast | Precancer | endothelial cell migration | 33/1080 | 279/18723 | 7.28e-05 | 1.44e-03 | 33 |
| GO:00901309 | Breast | Precancer | tissue migration | 40/1080 | 365/18723 | 7.48e-05 | 1.47e-03 | 40 |
| GO:00105953 | Breast | Precancer | positive regulation of endothelial cell migration | 20/1080 | 133/18723 | 7.59e-05 | 1.48e-03 | 20 |
| GO:00106329 | Breast | Precancer | regulation of epithelial cell migration | 33/1080 | 292/18723 | 1.74e-04 | 2.86e-03 | 33 |
| GO:00506786 | Breast | Precancer | regulation of epithelial cell proliferation | 40/1080 | 381/18723 | 1.88e-04 | 3.03e-03 | 40 |
| GO:00016678 | Breast | Precancer | ameboidal-type cell migration | 47/1080 | 475/18723 | 2.19e-04 | 3.35e-03 | 47 |
| GO:00105943 | Breast | Precancer | regulation of endothelial cell migration | 27/1080 | 232/18723 | 4.12e-04 | 5.55e-03 | 27 |
| GO:00506793 | Breast | Precancer | positive regulation of epithelial cell proliferation | 24/1080 | 207/18723 | 8.88e-04 | 1.02e-02 | 24 |
| GO:00018373 | Breast | Precancer | epithelial to mesenchymal transition | 19/1080 | 157/18723 | 1.78e-03 | 1.75e-02 | 19 |
| GO:0035767 | Breast | Precancer | endothelial cell chemotaxis | 7/1080 | 32/18723 | 1.97e-03 | 1.89e-02 | 7 |
| GO:00434912 | Breast | Precancer | protein kinase B signaling | 23/1080 | 211/18723 | 2.53e-03 | 2.30e-02 | 23 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0520514 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
| hsa0452018 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
| hsa052309 | Breast | Precancer | Central carbon metabolism in cancer | 13/684 | 70/8465 | 3.57e-03 | 2.17e-02 | 1.66e-02 | 13 |
| hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0520515 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
| hsa0452019 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
| hsa0523012 | Breast | Precancer | Central carbon metabolism in cancer | 13/684 | 70/8465 | 3.57e-03 | 2.17e-02 | 1.66e-02 | 13 |
| hsa0471424 | Breast | IDC | Thermogenesis | 75/867 | 232/8465 | 8.41e-21 | 3.04e-19 | 2.27e-19 | 75 |
| hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
| hsa0481014 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
| hsa0471434 | Breast | IDC | Thermogenesis | 75/867 | 232/8465 | 8.41e-21 | 3.04e-19 | 2.27e-19 | 75 |
| hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
| hsa0481015 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
| hsa0471443 | Breast | DCIS | Thermogenesis | 74/846 | 232/8465 | 8.72e-21 | 3.13e-19 | 2.30e-19 | 74 |
| hsa0520542 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
| hsa0481023 | Breast | DCIS | Regulation of actin cytoskeleton | 35/846 | 229/8465 | 6.89e-03 | 3.37e-02 | 2.48e-02 | 35 |
| hsa0452024 | Breast | DCIS | Adherens junction | 17/846 | 93/8465 | 9.95e-03 | 4.40e-02 | 3.24e-02 | 17 |
| hsa0471453 | Breast | DCIS | Thermogenesis | 74/846 | 232/8465 | 8.72e-21 | 3.13e-19 | 2.30e-19 | 74 |
| hsa0520552 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| FGF7 | FGFR1 | FGF7_FGFR1 | FGF | Breast | ADJ |
| FGF2 | FGFR1 | FGF2_FGFR1 | FGF | Breast | DCIS |
| FGF7 | FGFR1 | FGF7_FGFR1 | FGF | Breast | DCIS |
| FGF2 | FGFR1 | FGF2_FGFR1 | FGF | Breast | Healthy |
| FGF7 | FGFR1 | FGF7_FGFR1 | FGF | Breast | Healthy |
| FGF7 | FGFR1 | FGF7_FGFR1 | FGF | Breast | IDC |
| FGF7 | FGFR1 | FGF7_FGFR1 | FGF | Breast | Precancer |
| FGF7 | FGFR1 | FGF7_FGFR1 | FGF | Cervix | ADJ |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | Cervix | ADJ |
| FGF1 | FGFR1 | FGF1_FGFR1 | FGF | Cervix | CC |
| FGF7 | FGFR1 | FGF7_FGFR1 | FGF | Cervix | CC |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | Cervix | Healthy |
| FGF7 | FGFR1 | FGF7_FGFR1 | FGF | Cervix | Healthy |
| FGF2 | FGFR1 | FGF2_FGFR1 | FGF | Cervix | Precancer |
| FGF7 | FGFR1 | FGF7_FGFR1 | FGF | Cervix | Precancer |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | Cervix | Precancer |
| FGF9 | FGFR1 | FGF9_FGFR1 | FGF | CRC | AD |
| NCAM1 | FGFR1 | NCAM1_FGFR1 | NCAM | CRC | ADJ |
| FGF2 | FGFR1 | FGF2_FGFR1 | FGF | CRC | ADJ |
| FGF7 | FGFR1 | FGF7_FGFR1 | FGF | CRC | CRC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FGFR1 | SNV | Missense_Mutation | c.684N>G | p.Phe228Leu | p.F228L | P11362 | protein_coding | tolerated(0.1) | benign(0.185) | TCGA-3C-AALJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FGFR1 | SNV | Missense_Mutation | novel | c.2500N>A | p.Glu834Lys | p.E834K | P11362 | protein_coding | tolerated(0.66) | benign(0.356) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FGFR1 | SNV | Missense_Mutation | novel | c.1205N>T | p.Ser402Leu | p.S402L | P11362 | protein_coding | deleterious(0.03) | probably_damaging(0.921) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| FGFR1 | SNV | Missense_Mutation | c.409N>C | p.Ser137Arg | p.S137R | P11362 | protein_coding | tolerated(0.67) | benign(0.015) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| FGFR1 | insertion | Frame_Shift_Ins | novel | c.1977_1978insAG | p.Val660ArgfsTer4 | p.V660Rfs*4 | P11362 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| FGFR1 | insertion | Nonsense_Mutation | novel | c.1975_1976insTCTACACCCACCAGAGTGATGTGTGAGTTTGTA | p.Arg658_Asn659insIleTyrThrHisGlnSerAspValTerValCys | p.R658_N659insIYTHQSDV*VC | P11362 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| FGFR1 | insertion | Frame_Shift_Ins | novel | c.2217_2218insAAAAGAAAAAAAAGGAAAAT | p.Leu740LysfsTer12 | p.L740Kfs*12 | P11362 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| FGFR1 | SNV | Missense_Mutation | novel | c.278N>G | p.Asp93Gly | p.D93G | P11362 | protein_coding | tolerated(0.54) | benign(0.16) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FGFR1 | SNV | Missense_Mutation | novel | c.2359N>T | p.Arg787Cys | p.R787C | P11362 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
| FGFR1 | insertion | Frame_Shift_Ins | novel | c.2338_2339insGGGAA | p.Gln780ArgfsTer14 | p.Q780Rfs*14 | P11362 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2260 | FGFR1 | KINASE, DRUG RESISTANCE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | NGM313 | |||
| 2260 | FGFR1 | KINASE, DRUG RESISTANCE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | Lucitanib | LUCITANIB | 27126994 | |
| 2260 | FGFR1 | KINASE, DRUG RESISTANCE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 354702240 | PEMIGATINIB | |
| 2260 | FGFR1 | KINASE, DRUG RESISTANCE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | Crizotinib | CRIZOTINIB | 28476735 | |
| 2260 | FGFR1 | KINASE, DRUG RESISTANCE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | CENISERTIB | CENISERTIB | ||
| 2260 | FGFR1 | KINASE, DRUG RESISTANCE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | FGF/VEGF RECEPTOR TYROSINE KINASE INHIBITOR, PD173074 | 27535980 | ||
| 2260 | FGFR1 | KINASE, DRUG RESISTANCE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | AZD4547 | |||
| 2260 | FGFR1 | KINASE, DRUG RESISTANCE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | CHEMBL52885 | ENMD-981693 | |
| 2260 | FGFR1 | KINASE, DRUG RESISTANCE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | AST-487 | AST-487 | ||
| 2260 | FGFR1 | KINASE, DRUG RESISTANCE, TYROSINE KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | BGJ398 | INFIGRATINIB |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |